Stock CPIX CUMBERLAND PHARMACEUTICALS INC.
Add to a list
To use this feature you must be a member
Log inSign up

Other languages Cumberland Pharmaceuticals Inc.

Equities

CPIX

US2307701092

Delayed Nasdaq
Other stock markets
 04:30:00 2024-04-25 pm EDT 		5-day change 1st Jan Change
1.7 USD +5.59% Intraday chart for Cumberland Pharmaceuticals Inc. +3.03% -5.12%
Mar. 13 Tranche Update on Cumberland Pharmaceuticals Inc.'s Equity Buyback Plan announced on May 13, 2010. CI
Mar. 05 Cumberland Pharmaceuticals Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI

Other languages

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Cumberland Pharmaceuticals Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
Cumberland Pharmaceuticals Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023
Cumberland Pharmaceuticals Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
Cumberland Pharmaceuticals Seeks Acquisitions
Cumberland Pharmaceuticals Inc. Announces New Antimicrobial Agents and Chemotherapy Detaining the Results of the First Clinical Study Investigating the Safety and Pharmacokinetics of Vibativ®? Injection in Children 2 to 17 Years of Age
Cumberland Pharmaceuticals Inc. Announces New Publication in Antimicrobial Agents and Chemotherapy Detaining the Safety and Pharmacokinetics of Vibativ Injection in Children 2 to 17 Years of Age
Cumberland Pharmaceuticals Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023
Cumberland Pharmaceuticals Inc. Presents Results from an Interim Analysis for the FIGHT DMD Trial
Cumberland Pharmaceuticals Inc. Announces the Publication of Positive Results from Clinical Study Investigating the Safety and Pharmacokinetics of Caldolor in Newborn Infants, Published in the Journal Pediatric Drugs
Cumberland Pharmaceuticals Inc. Announces FDA Clearance of IND for New Treatment of Idiopathic Pulmonary Fibrosis
U.S. Food and Drug Administration Approves Cumberland Pharmaceuticals Inc.'s Expanded Lab Labulation for Caldolor
Cumberland Pharmaceuticals Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023
Cumberland Pharmaceuticals Inc. Announces that it Expects that its Caldolor ® ( Ibuprofen ) Injection Product Should Be Eligible for Special Medicare Reimbursement Under the Non-Opioids Prevent Addiction in the Nation Act
Cumberland Pharmaceuticals Inc. Reports Earnings Results for the Full Year Ended December 31, 2022
Cumberland Pharmaceuticals Seeks Acquisitions
Cumberland Pharmaceuticals Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2022
Cumberland Pharmaceuticals Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2022
Cumberland Pharmaceuticals Inc. Announces Demise of Joey A. Jacobs, Member of Board of Directors
Cumberland Pharmaceuticals Inc. Announces Approval of Supplemental New Drug Application from U.S. Food and Drug Administration
Cumberland Pharmaceuticals Seeks Acquisitions
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. CPIX Stock
  4. News Cumberland Pharmaceuticals Inc.
  5. Other languages